Moderna Inc (NASDAQ:MRNA) CEO Sells $588,724.72 in Stock

Moderna Inc (NASDAQ:MRNA) CEO Stephane Bancel sold 8,587 shares of the stock in a transaction on Monday, September 21st. The shares were sold at an average price of $68.56, for a total transaction of $588,724.72. Following the transaction, the chief executive officer now directly owns 6,663,868 shares in the company, valued at approximately $456,874,790.08. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Stephane Bancel also recently made the following trade(s):

  • On Friday, September 18th, Stephane Bancel sold 11,046 shares of Moderna stock. The shares were sold at an average price of $67.71, for a total transaction of $747,924.66.
  • On Wednesday, September 16th, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $67.69, for a total transaction of $609,210.00.
  • On Friday, September 11th, Stephane Bancel sold 11,046 shares of Moderna stock. The shares were sold at an average price of $58.42, for a total transaction of $645,307.32.
  • On Friday, September 4th, Stephane Bancel sold 11,046 shares of Moderna stock. The shares were sold at an average price of $61.87, for a total transaction of $683,416.02.
  • On Wednesday, September 2nd, Stephane Bancel sold 18,247 shares of Moderna stock. The shares were sold at an average price of $63.22, for a total transaction of $1,153,575.34.
  • On Wednesday, August 26th, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $67.45, for a total transaction of $607,050.00.
  • On Thursday, August 20th, Stephane Bancel sold 27,824 shares of Moderna stock. The shares were sold at an average price of $67.46, for a total transaction of $1,877,007.04.
  • On Thursday, August 13th, Stephane Bancel sold 19,000 shares of Moderna stock. The shares were sold at an average price of $72.22, for a total transaction of $1,372,180.00.
  • On Monday, August 10th, Stephane Bancel sold 19,143 shares of Moderna stock. The shares were sold at an average price of $74.23, for a total transaction of $1,420,984.89.
  • On Wednesday, August 5th, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $77.49, for a total transaction of $697,410.00.

NASDAQ:MRNA opened at $65.17 on Friday. The firm has a market cap of $25.72 billion, a P/E ratio of -46.55 and a beta of 0.47. Moderna Inc has a fifty-two week low of $13.53 and a fifty-two week high of $95.21. The firm has a 50-day simple moving average of $66.87 and a two-hundred day simple moving average of $57.30.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.05. The business had revenue of $66.35 million during the quarter, compared to analyst estimates of $24.24 million. Moderna had a negative net margin of 461.42% and a negative return on equity of 27.85%. The firm’s quarterly revenue was up 407.2% on a year-over-year basis. Sell-side analysts anticipate that Moderna Inc will post -1.54 EPS for the current fiscal year.

Hedge funds have recently made changes to their positions in the company. Bessemer Group Inc. bought a new stake in shares of Moderna in the second quarter worth approximately $27,000. Corbenic Partners LLC bought a new stake in shares of Moderna in the second quarter worth approximately $32,000. BDO Wealth Advisors LLC bought a new stake in shares of Moderna in the second quarter worth approximately $32,000. Global Wealth Management Investment Advisory Inc. grew its stake in shares of Moderna by 124.0% in the second quarter. Global Wealth Management Investment Advisory Inc. now owns 560 shares of the company’s stock worth $36,000 after acquiring an additional 310 shares during the period. Finally, Pacitti Group Inc. grew its stake in shares of Moderna by 175.6% in the second quarter. Pacitti Group Inc. now owns 620 shares of the company’s stock worth $44,000 after acquiring an additional 395 shares during the period. Hedge funds and other institutional investors own 55.04% of the company’s stock.

MRNA has been the subject of several analyst reports. Goldman Sachs Group set a $105.00 price target on shares of Moderna and gave the company a “buy” rating in a research report on Monday, July 27th. JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Moderna in a research report on Thursday, August 6th. BidaskClub raised shares of Moderna from a “hold” rating to a “buy” rating in a research report on Thursday, September 17th. Zacks Investment Research raised shares of Moderna from a “hold” rating to a “buy” rating and set a $86.00 target price for the company in a research report on Tuesday, July 21st. Finally, Barclays assumed coverage on shares of Moderna in a research report on Monday, June 8th. They issued an “overweight” rating and a $68.00 target price for the company. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and sixteen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $87.44.

Moderna Company Profile

Moderna, Inc, a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Featured Article: What is a Market Correction?

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.